Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer.

Journal Article (Journal Article;Review)

Despite regulatory approval of several immune-based treatments for cancer in the past decade, a number of barriers remain to be addressed in order to fully harness the therapeutic potential of the immune system and provide benefits for patients with cancer. As part of the Cancer Moonshot initiative, the Immuno-Oncology Translational Network (IOTN) was established to accelerate the translation of basic discoveries to improve immunotherapy outcomes across the spectrum of adult cancers and to develop immune-based approaches that prevent cancers before they occur. The IOTN currently consists of 32 academic institutions in the USA. By leveraging cutting-edge preclinical research in immunotherapy and immunoprevention, open data and resource sharing, and fostering highly collaborative team science across the immuno-oncology ecosystem, the IOTN is designed to accelerate the generation of novel mechanism-driven immune-based cancer prevention and therapies, and the development of safe and effective personalized immuno-oncology approaches.

Full Text

Duke Authors

Cited Authors

  • Annapragada, A; Sikora, A; Bollard, C; Conejo-Garcia, J; Cruz, CR; Demehri, S; Demetriou, M; Demirdjian, L; Fong, L; Horowitz, M; Hutson, A; Kadash-Edmondson, K; Kufe, D; Lipkin, S; Liu, S; McCarthy, C; Morgan, M; Morris, Z; Pan, Y; Pasquini, M; Schoenberger, S; Van Allen, E; Vilar, E; Xing, Y; Zha, W; IOTN Consortium, ; Odunsi, A

Published Date

  • June 2020

Published In

Volume / Issue

  • 8 / 1

PubMed ID

  • 32554617

Pubmed Central ID

  • PMC7304845

Electronic International Standard Serial Number (EISSN)

  • 2051-1426

Digital Object Identifier (DOI)

  • 10.1136/jitc-2020-000796


  • eng

Conference Location

  • England